• Accueil >
  • Publications >
  • High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial

High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial

1 sept. 2015Breast Cancer Research and Treatment

DOI : 10.1007/s10549-015-3552-7

Auteurs

Céline Callens, Marc Debled, Marc Delord, Isabelle Turbiez-Stalain, Corinne Veyret, Ivan Bièche, Etienne Brain